Want to join the conversation?
During 2Q16, $GILD's GAAP and non-GAAP R&D expenses rose, mainly as a result of the company's purchase of US FDA priority review voucher and the overall progress of its clinical studies. These expense also include the company's purchase of Nimbus Apollo, Inc. During the quarter, $GILD utilized $1Bil on stock repurchases.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.